The content on this site is intended for healthcare professionals only
Chronic lymphocytic leukaemia (CLL) treatment is evolving with a focus on limited duration therapies.
Promising combinations like BCL2 inhibitor venetoclax with obinutuzumab are being explored.
New strategies are moving away from traditional chemo immunotherapy towards innovative doublets and triplets. Emerging therapies, including BTK degraders and CAR T-cell treatments, aim to personalise care based on minimal residual disease assessments, ultimately enhancing patient outcomes.
Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG
ASCO 2025: Developments in the treatment of soft tissue sarcoma
Memorial Cancer Institute's Best of ASCO® 2025
Updates on gastrointestinal cancer treatments ASCO 2025
Advancements in gastrointestinal cancer treatments at ASCO 2025
Future of chemotherapy and targeted therapies
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Breast cancer screening global approaches
